Suicidal ideation — the experience of thoughts about ending one’s life, ranging from passive wishes to die to active plans — affects a significant proportion of individuals with treatment-resistant depression, PTSD, and other serious mental health conditions, and it represents one of the most urgent clinical challenges in psychiatry. Research published in journals including JAMA Psychiatry has documented that IV ketamine can produce rapid reductions in suicidal ideation — sometimes within hours of a single infusion — through mechanisms distinct from any other pharmacological intervention currently available. At Ketamine Wellness Institute Jacksonville, we serve patients for whom the urgency of symptom relief is not abstract, and we want to provide a clear, honest, and clinically grounded picture of what the current evidence supports.
Crisis Notice: If you or someone you care for is experiencing a mental health emergency or suicidal crisis, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988, or go to the nearest emergency department. The information in this article is educational and does not replace emergency clinical care.
What Suicidal Ideation Is — and What It Is Not
Suicidal ideation is not a diagnosis but a symptom — one that can occur across multiple psychiatric conditions including major depressive disorder, treatment-resistant depression, PTSD, bipolar disorder, and others. Its intensity ranges from passive ideation — vague wishes that one did not exist, without intent or plan — to active ideation with a specific plan and means. Clinical management requires accurate assessment of ideation severity, intent, and access to means, and it requires clinicians who take every presentation seriously regardless of where it falls on the severity spectrum. Dr. Aravind Reddy, MD approaches this aspect of care with the seriousness and attentiveness that his dual board certification and his commitment to direct physician oversight reflect.
What the Research Shows: Ketamine’s Rapid Anti-Suicidal Effects
The research base for ketamine’s rapid anti-suicidal effects is one of the most compelling findings in recent psychiatric literature. A landmark study published in JAMA Psychiatry by Murrough and colleagues specifically examined ketamine’s effects on suicidal ideation in patients with treatment-resistant depression and found significant reductions within hours of infusion. Subsequent research has replicated these findings across multiple samples and settings. The mechanism is believed to involve ketamine’s acute effects on the glutamate system — specifically the rapid synaptogenesis and BDNF elevation that restore prefrontal cortical function — alongside possible modulation of opioid receptors that influence the emotional component of the suicidal experience. We present these mechanisms as hypotheses supported by evidence, not as established certainties.
IV Ketamine vs. SPRAVATO®: Understanding the Regulatory Distinction
The regulatory status of IV ketamine for suicidal ideation requires clarification because it is often misunderstood. SPRAVATO® (esketamine nasal spray) is FDA-approved for major depressive disorder with acute suicidal ideation or behavior (MDD with ASIB) — this is a distinct and specific indication. IV ketamine’s use for suicidal ideation is off-label — not FDA-approved for this indication. These are different drugs, different formulations, different approval pathways, and different clinical protocols. We do not offer SPRAVATO® at our clinic; we offer IV ketamine, which is administered under a different set of clinical parameters and with the direct physician supervision of Dr. Reddy. Results vary by individual, and this information is educational — not clinical advice.
Safety Assessment and the KWI Jacksonville Clinical Approach
The clinical context in which IV ketamine is administered for patients with active or recent suicidal ideation matters enormously. This is not a treatment that should be initiated without a thorough psychiatric safety assessment. Dr. Reddy’s intake evaluation specifically addresses suicidal ideation history — its intensity, duration, chronicity, and current level — and this evaluation informs clinical candidacy and the safety planning that precedes any infusion. For patients with active suicidal ideation, IV ketamine is most appropriately considered as an adjunct to, not a replacement for, ongoing psychiatric care and crisis planning. We are explicit with patients that the rapid reduction in suicidal ideation that research has documented is a clinical opportunity — a window in which ongoing care, safety planning, and therapeutic work may be most accessible. Discuss with your provider how IV ketamine fits within the broader framework of your psychiatric safety plan.
Addressing Stigma and Supporting Families Through Treatment
One barrier that families face is the uncertainty of how to interpret a loved one’s suicidal ideation and whether to seek specialized ketamine treatment versus emergency psychiatric care. The general guidance is that active suicidal ideation with intent and plan is a psychiatric emergency requiring emergency services, not an outpatient infusion clinic. Passive ideation, recurrent ideation in the context of chronic treatment-resistant depression, or suicidal ideation that has recently decreased in intensity but has not remitted are presentations that may be appropriate for outpatient evaluation and, if clinically indicated, IV ketamine therapy. The distinction between these presentations is clinical, not intuitive, and we encourage families to contact us with questions rather than making this determination without clinical input.
The second barrier is the stigma that sometimes accompanies disclosure of suicidal ideation — a concern that honest reporting will result in involuntary hospitalization or loss of autonomy. We want to address this directly: the clinical goal is not to respond to every disclosure of suicidal thoughts with the highest-intensity intervention available, but to assess the actual level of risk and respond proportionately. Dr. Reddy’s intake process is designed to facilitate honest disclosure in a clinical relationship characterized by respect for the patient’s autonomy and dignity. Patients who have chronic suicidal ideation as a feature of long-standing depression are not, by definition, in acute crisis; they are experiencing a serious chronic symptom that deserves serious chronic treatment. We treat it that way.
For families supporting a loved one through treatment for depression and suicidal ideation, we encourage maintaining open communication with the clinical team, understanding the safety planning that is part of any serious treatment program, and supporting the patient’s engagement with ongoing mental health care between sessions. The rapid anti-suicidal effects of ketamine, where they occur, are clinically significant — but they are most durably meaningful when they are used to strengthen the broader therapeutic and safety structures in a patient’s life. Results vary by individual, and we encourage every patient and family member with questions to reach out to our clinic directly.
Frequently Asked Questions
Can IV ketamine help if I have thoughts of suicide?
Research has documented rapid reductions in suicidal ideation following IV ketamine infusions in patients with treatment-resistant depression. This is an off-label use, not FDA-approved for this indication, and the clinical decision to use IV ketamine for this presentation requires a thorough psychiatric safety assessment by a qualified physician. If you are experiencing active suicidal ideation with intent or plan, contact 988 or go to the nearest emergency department. Discuss with your provider whether IV ketamine is an appropriate clinical option given your specific situation.
Is IV ketamine or SPRAVATO® approved for suicidal ideation?
SPRAVATO® is FDA-approved specifically for major depressive disorder with acute suicidal ideation or behavior (MDD with ASIB) — that is a distinct and specific FDA indication. IV ketamine’s use for suicidal ideation is off-label. We do not offer SPRAVATO® at our clinic. IV ketamine is administered under direct physician supervision by Dr. Reddy.
How quickly does ketamine reduce suicidal thoughts?
Clinical research has documented reductions in suicidal ideation scores within hours of a single infusion in some patients. The speed of anti-suicidal effects has been one of ketamine’s most clinically compelling findings in the research literature. Results vary by individual, and not every patient experiences the same degree or speed of response.
What safety assessments are done before treating a patient with suicidal ideation?
Dr. Reddy’s intake evaluation specifically includes assessment of suicidal ideation — history, intensity, chronicity, current level, intent, and plan. This evaluation informs clinical candidacy, the infusion parameters, and the safety planning that is established before any session. Patients with active suicidal crisis are directed to emergency psychiatric resources, not to outpatient ketamine therapy.
Should a family member accompany me to the consultation if I have been having thoughts of suicide?
Family support is welcome and can be helpful, though not required. The clinical relationship is primarily between the patient and Dr. Reddy. If family members want to be involved in the consultation process, we encourage a conversation with the patient about how they want that to work, and we welcome that conversation with the patient’s consent.
Key Takeaways
- Research has documented rapid reductions in suicidal ideation following IV ketamine infusions; this is one of ketamine’s most clinically significant findings in the psychiatric literature.
- IV ketamine for suicidal ideation is off-label; SPRAVATO® is FDA-approved for MDD with acute suicidal ideation — they are different drugs administered differently.
- Active suicidal ideation with intent or plan is a psychiatric emergency requiring emergency services — not an outpatient infusion clinic.
- Dr. Reddy’s intake evaluation specifically includes psychiatric safety assessment before any infusion for patients with suicidal ideation.
- Results vary by individual; the rapid anti-suicidal effects of ketamine are most meaningful when integrated into ongoing psychiatric care and safety planning.
For patients managing the weight of suicidal ideation alongside treatment-resistant depression, the clinical evidence for IV ketamine’s rapid effects offers something genuinely meaningful: the possibility of relief on a timeline that standard treatments cannot match. At Ketamine Wellness Institute Jacksonville, we approach this aspect of care with the seriousness, attentiveness, and clinical rigor it demands — physician-supervised, safety-assessed, and integrated into a broader care plan. If you or someone you care for has questions about whether IV ketamine may be appropriate, we encourage you to reach out to Dr. Reddy for a consultation.
If you are in crisis now, please call or text 988 (Suicide and Crisis Lifeline) or go to your nearest emergency department.
About Dr. Aravind Reddy, MD
Dr. Aravind Reddy is a double board-certified anesthesiologist and interventional pain medicine specialist who leads Ketamine Wellness Institute Jacksonville. He completed his residency and fellowship in pain management at the University of North Carolina in Chapel Hill. Born and raised in Tallahassee, Florida, Dr. Reddy returned to North Florida to serve the Jacksonville community. He is committed to compassionate, multi-disciplinary care for patients with complex pain and mental health conditions, providing direct physician oversight at every ketamine infusion session. The clinic operates from Jacksonville Beach and serves patients across the Northeast Florida region.
References
- 988 Suicide and Crisis Lifeline: https://988lifeline.org/
- National Institute of Mental Health: https://www.nimh.nih.gov/health/topics/suicide-prevention
- American Psychiatric Association: https://www.psychiatry.org/patients-families/suicide
- JAMA Psychiatry (ketamine for suicidal ideation research context): https://jamanetwork.com/journals/jamapsychiatry
Medical Disclaimer
The content of this article is provided by Ketamine Wellness Institute Jacksonville for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Ketamine’s use for suicidal ideation is off-label and not FDA-approved for this indication. SPRAVATO® is FDA-approved for MDD with acute suicidal ideation — a separate indication and drug. If you are in crisis, contact 988 or go to your nearest emergency department. Individual results vary. Always discuss treatment options, risks, and benefits with a qualified healthcare provider.